Amarin Corp Plc\Uk
$5.60B- Market cap
- $5.73B
- Debt
- +$177.39M
- Cash
- −$302.59M
Capital structure 97% equity / 3% debt · EV / Revenue 26.21x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt cap
Decision snapshot: AMRN stock price at premium vs RMD $13.63 current versus $3.00 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at RMD's multiple
Implied fair value · at AMRN's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: AMRN FY 2025 (ended Dec 31, 2025) · RMD FY 2026 (ended Jun 30, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 97% equity / 3% debt · EV / Revenue 26.21x
Capital structure 98% equity / 2% debt · EV / Revenue 5.68x · EV / EBITDA 15.13x
RMD carries the larger enterprise value at $32.13B against $5.60B; RMD trades on the lower EV / Revenue multiple (5.68x vs 26.21x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
AMARIN CORP PLC\UK · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
ResMed Inc. · implied price per share
Bear
$145.79
Base
$173.17
Bull
$210.12
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.39x
0.10x
Net debt / EBITDA
Leverage against operating earnings
3.79x
-0.38x
Cash and equivalents
Liquid reserves on the balance sheet
$302.59M
$1.47B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LIGAND PHARMACEUTICALS INC
AMRN vs LGND
Harmony Biosciences Holdings, Inc.
AMRN vs HRMY
SUPERNUS PHARMACEUTICALS, INC.
AMRN vs SUPN
Viatris Inc
AMRN vs VTRS
Organon & Co.
AMRN vs OGN
INCYTE CORP
AMRN vs INCY
KONINKLIJKE PHILIPS NV
AMRN vs PHG
MASIMO CORP
AMRN vs MASI
Inspire Medical Systems, Inc.
AMRN vs INSP
Sleep Number Corp
AMRN vs SNBR
$177.39M
$659.37M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe AMRN can reverse revenue declines and materially improve operating margins toward RMD-like levels, then the stock may merit holding; otherwise, the data support avoiding or reducing exposure because AMRN trades at a far richer valuation despite weaker growth, profitability, and returns.
AMRN's current price of $16.37 implies a P/S-based value of just $3.04, or -81.4% downside, versus its current trading level. The gap is reinforced by AMRN's much richer multiples than RMD despite materially weaker fundamentals.
Supporting Metrics